U.S. 503b Compounding Pharmacies Market By Molecule (Esmolol, Vancomycin, Epinephrine, Fentanyl/ Bupivacaine, Adenocaine, Morphine, Amiodarone, Bupivacaine, Lidocaine), and Other Molecules), By Packaging (Vials, Prefilled Syringes, Ampoules, Syringes, and Others)

Key Highlights of the report

How are the major segments performing in the U.S. 503b compounding pharmacies market?

• In 2022, the phenylephrine segment accounted for the largest market share as it is widely used to relieve nasal discomfort.
• In 2022, the prefilled syringes segment was anticipated to hold a prominent share in the U.S. 503b compounding pharmacies market. Increasing demands for efficient, easy-to-use drug delivery devices and healthcare professionals’ efforts to reduce hospital errors.

What is the Market Size of U.S. 503b Compounding Pharmacies regarding value?

The U.S. 503b compounding pharmacies market is anticipated to grow at a substantial CAGR of 7.80% in the upcoming years. The U.S. 503b compounding pharmacies industry was estimated to be worth USD 1.1 billion in 2022 and was expected to be worth USD 1.9 billion by 2030.

How is US Market Performing in the 503b Compounding Pharmacies market?

In 2022, compounding pharmacies in the U.S. are seeing increased demand for pain management drugs. According to the National Health Interview Survey, in 2019, 50.2 million Americans (20.5%) reported chronic pain on most days. Knees, backs, feet, and hips are the most common areas of pain. Compounded medications are also a good method of relieving pain. Creams from compounded medications provide instant relief when applied directly to the affected area. Further, compounding pharmacies collaborate with healthcare providers to create customized pain management treatment options and dosages. Such scenarios are expected to drive market growth in the next few years.

How is the economy impacting the U.S. 503b Compounding Pharmacies growth?

Pharmacy staff is struggling to fill the demand for medicines during times of covid-19 pandemic. Because of this, 503B outsourcing facilities are invaluable partners for hospitals and health systems in addressing drug scarcity and its impact on patients during this pandemic. According to the Drug Quality and Security Act, passed in 2013, 503B outsourcing facilities could compound nonsterile and sterile drug products in advance of their providers’ needs if they met certain standards established by the federal government. With the surge in demand for critical care medicines caused by the pandemic, 503B facilities can supply hospitals when commercial manufacturers cannot supply.

What is the competitive environment of the U.S. 503b Compounding Pharmacies market?

The U.S. 503b compounding pharmacies industry’s competitive environment provides information on the entire economic profit made by suppliers and businesses, the sales and revenues created in this sector, the U.S. 503b compounding pharmacies market share, the business organization summary, the introduction of new products, and the opportunities for the industrial U.S. 503b compounding pharmacies market. For instance, in January 2022, in the Nephron 503B Outsourcing Facility operation, Nephron Pharmaceuticals Corporation launched a new syringe presentation, the Cyclic Olefin Copolymer Syringe (COC). In addition to 8.4% sodium bicarbonate injection, the company will also introduce a COC syringe for this product. By pursuing this strategy, the company will be able to grow its product portfolio in compounding pharmacies. Furthermore, in May 2022, A 503B outsourcing facility and a state-licensed pharmacy were acquired by Edgewood Pharmacy through Zoo, Wildlife Specializations. This strategy increased the company’s product portfolio, accelerating its market growth.

Executive Summary

What are the key trends in the U.S. 503b Compounding Pharmacies market?

• Over the forecast period, the U.S. 503B Compounding Pharmacies market is expected to grow due to an increased drug shortage. For example, the Drug Shortages Task Force of the U.S. Food and Drug Administration 2019 report titled ‘Drug Shortages: Root Causes and Potential Solutions’ explains that drug shortages are caused by a lack of incentives to produce less profitable drugs and logistical and regulatory obstacles. As stated in the report, hospitals must pay more for branded and alternative drugs when there is a shortage of low-cost generic drugs or obtain medications from compounding facilities. Therefore, such instances could contribute to the market’s growth in the near future.

How are Pharma Manufacturers Teaming Up with Stakeholders in U.S. 503b Compounding Pharmacies Market?

As geriatric patients suffering from chronic diseases demand more pain management therapies, the market is expected to grow over the forecast period. Chronic pain is a major concern among older adults suffering from chronic diseases, according to Progress in Neuro-Psychopharmacology and Biological Psychiatry Journal: 2019. CDC (The Centers for Disease Control and Prevention) reports that in 2018, the population aged 60 years and older had the highest number of pain management therapies prescribed. The market is projected to grow during the forecast period due to increasing product approvals and launches. For instance, in November 2020, Fagron Compounding Pharmacies launched new intravenous bags (IV bags) containing Fentanyl Hydromorphone and Midazolam. Furthermore, the company plans to add hormones, chemicals, and norepinephrine to its IV bag offerings. According to a the U.S. Food and Drug Administration (FDA), the U.S. has been suffering from a drug shortage for several years, and the outbreak of COVID-19 has made it worse. In addition to supply chain disruptions, manufacturing process delays and discontinuities, quality issues, and difficulties obtaining raw materials, shortages are often caused by supply chain disruptions. As a result of drug shortages, compounding pharmacies in the U.S. have gained additional opportunities. In addition, FDA has issued temporary guidance to federal facilities and state-licensed pharmacies, including hospital pharmacies and compounding pharmacies, that are not registered as outsourcing facilities with FDA. As a result of a shortage of drugs required for patient treatment, compounding certain medications for hospitalized patients was required during the public health emergency.

Which are the key investments by the U.S. 503b Compounding Pharmacies market players?

Leading players operating in the U.S. 503b compounding pharmacies market focus on expanding 503b compounding. Apart from this, players are concentrating on strategic mergers and acquisitions, collaborations and creating awareness among pharmacies via different associations formed to promote smart practices to serve more end users in the domestic market to gain a competitive edge. For instance, in May 2020, Wedgwood Pharmacy acquired Zoo, Wildlife Specializations to acquire 503B outsourcing facilities and a state-licensed pharmacy to enhance the company’s market position.

Some major players in the U.S. 503b compounding pharmacies market are Central Admixture Pharmacy Services, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd’S Prescription Shop, Edge Pharma, Imprimis NJOF, Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., IntegraDose Compounding services, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma.

What are the Major Driving Factors for the U.S. 503b Compounding Pharmacies Market?

Increasing investments by the key market players in research and development will boost the growth of the US compounding pharmacy market as they innovate and customize formulations to treat various diseases effectively. Market growth is significantly accelerated by the rising prevalence of cancer among the US population. In addition, the growing acceptance of compounding pharmacies in the US is fueled by favorable government reimbursement policies. In addition, the growth of effective compounding pharmacies is being driven by technological advancements. Combined with the strong healthcare infrastructure in the US, the US compounding pharmacy market is growing due to the presence of leading market players.

What are the Major Risks for the U.S. 503b Compounding Pharmacies Market?

As a result of increasing product recalls, the U.S. 503B compounding pharmacy market is expected to slow down. For example, in August 2019, the U.S. Food and Drug Administration requested a recall of sterile compounded drug products produced by Pacifico National Inc. This Melbourne-based outsourcing facility operates as AmEx Pharmacy. Because of significant quality and sterility concerns, compounded ophthalmic and other drug products pose unnecessary risks.

Which is the key packaging in the U.S. 503b Compounding Pharmacies market?

The prefilled syringes segment is expected to hold a prominent share of the U.S. 503b compounding pharmacies market during the forecast period. The pharmaceutical industry seeks new and more convenient ways to deliver drugs, which has led to the rapid growth of prefilled syringes as a unit-dose medication option. In its article published in June 2022 on self-care interventions, the World Health Organization noted that self-injectable contraception could reduce unintended pregnancy rates. Increasing efforts of healthcare professionals to reduce hospital errors and growing demand for easy-to-use drug delivery devices are driving the market.

What is the regulatory landscape for the U.S. 503b Compounding Pharmacies market?

The FDA authorizes 503A pharmacies to provide sterile medicines under patient-specific conditions to fill each patient’s unique prescription. They are also approved for use at home by the FDA. The FDA does not require 503A pharmacies to register with the FDA, nor do they need to follow current good manufacturing practices (cGMP). These regulatory relaxations will boost the demand for 503A compounding pharmacies.

What are the major players planning for the future of the U.S. 503b Compounding Pharmacies market?

Growing regional existence and investment in downstream applications are anticipated to deliver a competitive edge in the market. It was announced in January 2022 that Athenex would manufacture its 503B products at its Dunkirk facility under a preliminary agreement with ImmunityBio, Inc. Through this partnership, the company will gain a competitive advantage and expand its product line.

REPORT ATTRIBUTE	DETAILS
U.S. 503b Compounding Pharmacies Market by Value	Yes
U.S. 503b Compounding Pharmacies Market, Tornado Analysis	Yes
U.S. 503b Compounding Pharmacies Market, STAR Analysis	Yes
U.S. 503b Compounding Pharmacies Market, SRC Analysis	Yes
U.S. 503b Compounding Pharmacies Market Pricing Analysis	Yes (On Demand)
U.S. 503b Compounding Pharmacies Market Segment Analysis	By Molecule (Esmolol, Vancomycin, Epinephrine, Fentanyl/ Bupivacaine, Adenocaine, Morphine, Amiodarone, Bupivacaine, Lidocaine, Heparin, Ketamine, Dextrose, Hydromorphone, BKK (Bupivacaine, ketorolac, Ketamine), RKK (Ropivacaine, Ketorolac, Ketamine), RCK (Ropivacaine, Clonidine, Ketorolac), and Other Molecules) By Packaging (Vials, Prefilled Syringes, Ampoules, Syringes, and Others)
U.S. 503b Compounding Pharmacies Market Key Companies	Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd’S Prescription Shop, Edge Pharma, Imprimis NJOF, IntegraDose Compounding services, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma.
U.S. 503b Compounding Pharmacies Market Competitive Landscape	Market Share Analysis Competitive Benchmarking Key Players Market Positioning Geographical Presence Analysis Major Strategies Adopted

Segmentation of U.S. 503b Compounding Pharmacies Market-

U.S. 503b Compounding Pharmacies Market – By Molecule

• Acetaminophen
• Phenylephrine
• Midazolam
• Esmolol
• Vancomycin
• Epinephrine
• Adenocaine
• Fentanyl/ Bupivacaine
• Morphine
• Amiodarone
• Heparin
• Ketamine
• Dextrose
• Hydromorphone
• Bupivacaine
• Lidocaine
• BKK (Bupivacaine, ketorolac, Ketamine)
• RCK (Ropivacaine, Clonidine, Ketorolac)
• RKK (Ropivacaine, Ketorolac, Ketamine)
• Other Molecules

U.S. 503b Compounding Pharmacies Market – By Packaging

• Vials
• Prefilled Syringes
• Ampoules
• Syringes
• Others

CHAPTER NO. 1 : INTRODUCTION 12
1.1. Report Description 12
1.1.1. Purpose of the Report 12
1.1.2. USP & Key Offerings 12
1.2. Key Benefits for Stakeholders 12
1.3. Target Audience 13
1.4. Report Scope 13

CHAPTER NO. 2 : EXECUTIVE SUMMARY 15
2.1. 503B Compounding Pharmacies Market Snapshot 15
2.2. U.S. 503B Compounding Pharmacies Market, 2017 – 2030 (USD Million) 17

CHAPTER NO. 3 : COVID 19 IMPACT ANALYSIS 18
3.1. Impact Assessment of COVID-19 Pandemic 18

CHAPTER NO. 4 : 503B COMPOUNDING PHARMACIES MARKET – INDUSTRY ANALYSIS 23
4.1. Introduction 23
4.2. Market Drivers 25
4.2.1. Regulatory Environment 25
4.2.2. Drug Shortages 25
4.2.3. Personalized Medicine 25
4.2.4. Patient Safety Concerns 25
4.2.5. Increasing Chronic Diseases 26
4.2.6. Growing Aging Population 26
4.3. Market Restraints 27
4.3.1. Restraining Factor Analysis 27
4.3.2. Limited Product Range 27
4.3.3. Lack of Insurance Coverage 27
4.4. Market Opportunities 28
4.4.1. Increasing Demand for Customized Medications 28
4.4.2. Veterinary Compounding 28
4.4.3. Limited Drug Availability & Integrative Medicine and Alternative Therapies 28
4.4.4. Partnerships with Healthcare Providers 28
4.4.5. Technological Advancements & Telemedicine and E-commerce 28
4.5. Major Industry Challenges 30
4.5.1. Quality Control and Standardization 30
4.5.2. Market Competition 30
4.5.3. Supply Chain Complexity 30
4.6. Porter’s Five Forces Analysis 31
4.7. Value Chain Analysis 32
4.8. Technology Progress in Related Industry 33
4.9. Consumer Needs/Customer Preference Change 33

CHAPTER NO. 5 : KEY INVESTMENT POCKETS ANALYSIS 34
5.1. Top Investment Pockets 34
5.1.1.1. 503B Compounding Pharmacies Market Attractiveness Analysis, By Molecules 34
5.1.1.2. 503B Compounding Pharmacies Market Attractiveness Analysis, By Packaging 35
5.2. Product Life Cycle Analysis 36
5.3. Incremental Revenue Growth Opportunity, 2023 – 2030 38
5.3.1. Molecules 38
5.3.2. Packaging 39
5.4. Key Raw Materials & Suppliers 40
5.5. Major Buyers of Compounding Pharmacies 46
5.6. Distributors/Traders List 47

CHAPTER NO. 6 : MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS 48
6.1. Marketing Channel 48
6.1.1. Direct Marketing 48
6.1.2. Indirect Marketing 48
6.1.3. Marketing Channel Development Trend 48
6.2. Market Positioning 48
6.2.1. Pricing Strategy 49
6.2.2. Brand Strategy 49
6.2.3. Target Client 49

CHAPTER NO. 7 : MARKET POSITIONING OF KEY PLAYERS 50
7.1. Company Market Share Analysis –2020 and 2022 50
7.1.1. U.S. 503B Compounding Pharmacies Market: Company Market Share, 2022 50
7.1.2. U.S. 503B Compounding Pharmacies Market: Company Market Share, 2022 51
7.1. U.S. 503B Compounding Pharmacies Market Company Volume Market Share, 2022 52
7.2. U.S. 503B Compounding Pharmacies Market Company Revenue Market Share, 2022 53
7.3. Market Position of Key Players 2022 54
7.3.1. Market Position of Key Players, 2022 54
7.4. Strategic Developments 55
7.4.1. Acquisitions & Mergers, Expansion and Agreement 55

CHAPTER NO. 8 : 503B COMPOUNDING PHARMACIES MARKET – BY MOLECULES SEGMENT ANALYSIS 58
8.1. 503B Compounding Pharmacies Market Overview, by Molecules Segment 58
8.1.1. U.S. 503B Compounding Pharmacies Market Revenue Share, By Molecules, 2022 & 2030 58
8.2. Acetaminophen 60
8.3. Phenylephrine 60
8.4. Midazolam 61
8.5. Esmolol 61
8.6. Vancomycin 62
8.7. Epinephrine 62
8.8. Adenocaine 63
8.9. Fentanyl/ Bupivacaine 63
8.10. Morphine 64
8.11. Amiodarone 64
8.12. Heparin 65
8.13. Ketamine 65
8.14. Dextrose 66
8.15. Hydromorphone 66
8.16. Bupivacaine 67
8.17. Lidocaine 67
8.18. BKK (Bupivacaine, ketorolac, Ketamine) 68
8.19. RCK (Ropivacaine, Clonidine, Ketorolac) 68
8.20. RKK (Ropivacaine, Ketorolac, Ketamine) 69
8.21. Other Molecules 69

CHAPTER NO. 9 : 503B COMPOUNDING PHARMACIES MARKET – BY PACKAGING SEGMENT ANALYSIS 70
9.1. 503B Compounding Pharmacies Market Overview, by Packaging Segment 70
9.1.1. U.S. 503B Compounding Pharmacies Market Revenue Share, By Packaging, 2022 & 2030 70
9.2. Vials 71
9.3. Prefilled Syringes 71
9.4. Syringes 72
9.5. Others 73

CHAPTER NO. 10 : COMPANY PROFILES 74
10.1. Central Admixture Pharmacy Services, Inc. 74
10.1.1. Company Overview 74
10.1.2. Product Portfolio 75
10.1.3. Financial Overview 75
10.2. Nephron Pharmaceuticals Corporation 76
10.2.1. Company Overview 76
10.2.2. Product Portfolio 77
10.2.3. Financial Overview 77
10.3. QuVa Pharma 78
10.3.1. Company Overview 78
10.3.2. Product Portfolio 79
10.3.3. Financial Overview 79
10.4. Olympia Pharmacy 80
10.4.1. Company Overview 80
10.4.2. Product Portfolio 81
10.4.3. Financial Overview 81
10.5. ASP Cares 82
10.5.1. Company Overview 82
10.5.2. Product Portfolio 82
10.5.3. Financial Overview 83
10.6. Fagron Compounding Pharmacies 84
10.6.1. Company Overview 84
10.6.2. Product Portfolio 85
10.6.3. Financial Overview 85
10.7. Athenex, Inc. 86
10.7.1. Company Overview 86
10.7.2. Product Portfolio 87
10.7.3. Financial Overview 87
10.8. Optum 88
10.8.1. Company Overview 88
10.8.2. Product Portfolio 89
10.8.3. Financial Overview 89
10.9. Atlas Pharmaceuticals 90
10.9.1. Company Overview 90
10.9.2. Product Portfolio 91
10.9.3. Financial Overview 91
10.10. Empower Pharmacy 92
10.10.1. Company Overview 92
10.10.2. Product Portfolio 92
10.10.3. Financial Overview 93
10.11. Carie Boyd’S Prescription Shop 94
10.11.1. Company Overview 94
10.11.2. Product Portfolio 95
10.11.3. Financial Overview 95
10.12. Edge Pharma 96
10.12.1. Company Overview 96
10.12.2. Product Portfolio 96
10.12.3. Financial Overview 97
10.13. IntegraDose Compounding services 98
10.13.1. Company Overview 98
10.13.2. Product Portfolio 99
10.13.3. Financial Overview 99
10.14. Wells Pharma 100
10.14.1. Company Overview 100
10.14.2. Product Portfolio 100
10.14.3. Financial Overview 101
10.15. SCA Pharma 102
10.15.1. Company Overview 102
10.15.2. Product Portfolio 103
10.15.3. Financial Overview 103
10.16. Imprimis NJOF 104
10.16.1. Company Overview 104
10.16.2. Product Portfolio 105
10.16.3. Financial Overview 105

CHAPTER NO. 11 : RESEARCH METHODOLOGY 106
11.1. Research Methodology 106
11.2. Phase I – Secondary Research 107
11.3. Phase II – Data Modeling 107
11.3.1. Company Share Analysis Model 108
11.3.2. Revenue Based Modeling 108
11.4. Phase III – Primary Research 109
11.5. Research Limitations 110
11.5.1. Assumptions 110

List of Figures
FIG NO. 1. U.S. 503B Compounding Pharmacies Market Volume & Revenue, 2017 – 2030 (USD Million) 17
FIG NO. 2. Global 503B Compounding Pharmacies Market, 2020 – 2030 (USD Million) 20
FIG NO. 3. World merchandise trade volume, 2000‑2022 22
FIG NO. 4. Porter’s Five Forces Analysis for U.S. 503B Compounding Pharmacies Market 31
FIG NO. 5. Value Chain Analysis for U.S. 503B Compounding Pharmacies Market 32
FIG NO. 6. Market Attractiveness Analysis, By Molecules 34
FIG NO. 7. Market Attractiveness Analysis, By Packaging 35
FIG NO. 8. Product Life Cycle Analysis 36
FIG NO. 9. Incremental Revenue Growth Opportunity by Molecules 38
FIG NO. 10. Incremental Revenue Growth Opportunity by Packaging 39
FIG NO. 11. Key Raw Materials & Suppliers 40
FIG NO. 12. Major Buyers of Compounding Pharmacies) 46
FIG NO. 13. Distributors/Traders List 47
FIG NO. 14. Company Share Analysis, 2020 50
FIG NO. 15. Company Share Analysis, 2022 51
FIG NO. 16. 503B Compounding Pharmacies Market – Company Volume Market Share, 2022 (USD Million) 52
FIG NO. 17. 503B Compounding Pharmacies Market – Company Revenue Market Share, 2022 (Share %) 53
FIG NO. 18. Market Position of Key Players, 2022 54
FIG NO. 19. U.S. 503B Compounding Pharmacies Market Revenue Share, By Molecules 58
FIG NO. 20. U.S. 503B Compounding Pharmacies Market Revenue Share, By Molecules, 2030 59
FIG NO. 21. U.S. 503B Compounding Pharmacies Market for Acetaminophen, Volume & Revenue (USD Million) 2017 – 2030 60
FIG NO. 22. U.S. 503B Compounding Pharmacies Market for Phenylephrine, Volume & Revenue (USD Million) 2017 – 2030 60
FIG NO. 23. U.S. 503B Compounding Pharmacies Market for Midazolam, Volume & Revenue (USD Million) 2017 – 2030 61
FIG NO. 24. U.S. 503B Compounding Pharmacies Market for Esmolol, Volume & Revenue (USD Million) 2017 – 2030 61
FIG NO. 25. U.S. 503B Compounding Pharmacies Market for Vancomycin, Volume & Revenue (USD Million) 2017 – 2030 62
FIG NO. 26. U.S. 503B Compounding Pharmacies Market for Epinephrine, Volume & Revenue (USD Million) 2017 – 2030 62
FIG NO. 27. U.S. 503B Compounding Pharmacies Market for Adenocaine, Volume & Revenue (USD Million) 2017 – 2030 63
FIG NO. 28. U.S. 503B Compounding Pharmacies Market for Fentanyl/ Bupivacaine, Volume & Revenue (USD Million) 2017 – 2030 63
FIG NO. 29. U.S. 503B Compounding Pharmacies Market for Morphine, Volume & Revenue (USD Million) 2017 – 2030 64
FIG NO. 30. U.S. 503B Compounding Pharmacies Market for Amiodarone, Volume & Revenue (USD Million) 2017 – 2030 64
FIG NO. 31. U.S. 503B Compounding Pharmacies Market for Heparin, Volume & Revenue (USD Million) 2017 – 2030 65
FIG NO. 32. U.S. 503B Compounding Pharmacies Market for Ketamine, Volume & Revenue (USD Million) 2017 – 2030 65
FIG NO. 33. U.S. 503B Compounding Pharmacies Market for Dextrose, Volume & Revenue (USD Million) 2017 – 2030 66
FIG NO. 34. U.S. 503B Compounding Pharmacies Market for Hydromorphone, Volume & Revenue (USD Million) 2017 – 2030 66
FIG NO. 35. U.S. 503B Compounding Pharmacies Market for Bupivacaine, Volume & Revenue (USD Million) 2017 – 2030 67
FIG NO. 36. U.S. 503B Compounding Pharmacies Market for Lidocaine, Volume & Revenue (USD Million) 2017 – 2030 67
FIG NO. 37. U.S. 503B Compounding Pharmacies Market for BKK (Bupivacaine, ketorolac, Ketamine), Volume & Revenue (USD Million) 2017 – 2030 68
FIG NO. 38. U.S. 503B Compounding Pharmacies Market for RCK (Ropivacaine, Clonidine, Ketorolac), Volume & Revenue (USD Million) 2017 – 2030 68
FIG NO. 39. U.S. 503B Compounding Pharmacies Market for RKK (Ropivacaine, Ketorolac, Ketamine), Volume & Revenue (USD Million) 2017 – 2030 69
FIG NO. 40. U.S. 503B Compounding Pharmacies Market for Other Molecules, Volume & Revenue (USD Million) 2017 – 2030 69
FIG NO. 41. U.S. 503B Compounding Pharmacies Market Revenue Share, By Packaging, 2022 & 2030 70
FIG NO. 42. U.S. 503B Compounding Pharmacies Market for Vials, Volume & Revenue (USD Million) 2017 – 2030 71
FIG NO. 43. U.S. 503B Compounding Pharmacies Market for Prefilled Syringes, Volume & Revenue (USD Million) 2017 – 2030 71
FIG NO. 44. U.S. 503B Compounding Pharmacies Market for Ampoules, Volume & Revenue (USD Million) 2017 – 2030 72
FIG NO. 45. U.S. 503B Compounding Pharmacies Market for Syringes, Volume & Revenue (USD Million) 2017 – 2030 72
FIG NO. 46. U.S. 503B Compounding Pharmacies Market for Others, Volume & Revenue (USD Million) 2017 – 2030 73
FIG NO. 47. Research Methodology – Detailed View 106
FIG NO. 48. Research Methodology 107

List of Tables
TABLE NO. 1. : U.S. 503B Compounding Pharmacies Market: Snapshot 15
TABLE NO. 2. : Estimated Impact of The Coronavirus (Covid-19) Epidemic on 503B Compounding Pharmacies Market Size In 2022, By Scenario 20
TABLE NO. 3. : Drivers for the 503B Compounding Pharmacies Market: Impact Analysis 25
TABLE NO. 4. : Restraints for the 503B Compounding Pharmacies Market: Impact Analysis 27